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Measuring inconsistency in meta-analyses
Julian P T Higgins, Simon G Thompson, Jonathan J Deeks, Douglas G Altman
Cochrane Reviews have recently started including the quantity I 2 to help readers assess the
consistency of the results of studies in meta-analyses. What does this new quantity mean, and why is
assessment of heterogeneity so important to clinical practice?
Systematic reviews and meta-analyses can provide
convincing and reliable evidence relevant to many
aspects of medicine and health care.1 Their value is
especially clear when the results of the studies they
include show clinically important effects of similar
magnitude. However, the conclusions are less clear
when the included studies have differing results. In an
attempt to establish whether studies are consistent,
reports of meta-analyses commonly present a statisti-
cal test of heterogeneity. The test seeks to determine
whether there are genuine differences underlying the
results of the studies (heterogeneity), or whether the
variation in findings is compatible with chance alone
(homogeneity). However, the test is susceptible to the
number of trials included in the meta-analysis.We have
developed a new quantity, I 2, which we believe gives a
better measure of the consistency between trials in a
meta-analysis.
Need for consistency
Assessment of the consistency of effects across studies
is an essential part of meta-analysis. Unless we know
how consistent the results of studies are, we cannot
determine the generalisability of the findings of the
meta-analysis. Indeed, several hierarchical systems for
grading evidence state that the results of studies must
be consistent or homogeneous to obtain the highest
grading.2–4
Tests for heterogeneity are commonly used to
decide on methods for combining studies and for con-
cluding consistency or inconsistency of findings.5 6 But
what does the test achieve in practice, and how should
the resulting P values be interpreted?
Testing for heterogeneity
A test for heterogeneity examines the null hypothesis
that all studies are evaluating the same effect. The usual
test statistic (Cochran’s Q) is computed by summing the
squared deviations of each study’s estimate from the
overall meta-analytic estimate, weighting each study’s
contribution in the same manner as in the meta-
analysis.7 P values are obtained by comparing the
statistic with a 2 distribution with k−1 degrees of
freedom (where k is the number of studies).
The test is known to be poor at detecting true
heterogeneity among studies as significant. Meta-
analyses often include small numbers of studies,6 8 and
the power of the test in such circumstances is low.9 10
For example, consider the meta-analysis of ran-
domised controlled trials of amantadine for preventing
influenza (fig 1).11 The treatment effects in the eight
trials seem inconsistent: the reduction in odds vary
from 16% to 93%, with some of the confidence
intervals not overlapping. But the test of heterogeneity
yields a P value of 0.09, conventionally interpreted as
being non-significant. Because the test is poor at
detecting true heterogeneity, a non-significant result
cannot be taken as evidence of homogeneity. Using a
cut-off of 10% for significance12 ameliorates this prob-
lem but increases the risk of drawing a false positive
conclusion (type I error).10
Conversely, the test arguably has excessive power
when there are many studies, especially when those
studies are large. One of the largest meta-analyses in
the Cochrane Database of Systematic Reviews is of clinical
trials of tricyclic antidepressants and selective sero-
tonin reuptake inhibitors for treatment of depres-
sion.13 Over 15 000 participants from 135 trials are
included in the assessment of comparative drop-out
rates, and the test for heterogeneity is significant
(P = 0.005). However, this P value does not reasonably
describe the extent of heterogeneity in the results of
the trials. As we show later, a little inconsistency exists
among these trials but it does not affect the conclusion
of the review (that serotonin reuptake inhibitors have
lower discontinuation rates than tricyclic anti-
depressants).
Since systematic reviews bring together studies that
are diverse both clinically and methodologically,
heterogeneity in their results is to be expected.6 For
example, heterogeneity is likely to arise through diver-
sity in doses, lengths of follow up, study quality, and
inclusion criteria for participants. So there seems little
point in simply testing for heterogeneity when what
matters is the extent to which it affects the conclusions
of the meta-analysis.
Oker-Blom (1970)
Muldoon (1976)
Monto (1979)
Kantor (1980)
Pettersson (1980)
Quarles (1981)
Dolin (1982)
Reuman (1989)
Odds ratio=0.34 (95% CI=0.22 to 0.53)
Heterogeneity: Q=12.4, P=0.09
Trial
16/141
1/53
8/136
9/59
32/95
15/107
2/113
3/317
Drug
(n/N)
41/152
8/52
28/139
9/51
59/97
20/99
27/132
5/159
0.10.01 1 10 100
Odds ratio
Increased riskDecreased risk
Placebo
(n/N)
Odds ratio
(95% CI)
Fig 1 Eight trials of amantadine for prevention of influenza.11
Outcome is cases of influenza. Summary odds ratios calculated with
random effects method
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Quantifying heterogeneity: a better
approach
We developed an alternative approach that quantifies
the effect of heterogeneity, providing a measure of the
degree of inconsistency in the studies’ results.14 The
quantity, which we call I 2, describes the percentage of
total variation across studies that is due to heterogen-
eity rather than chance. I 2 can be readily calculated
from basic results obtained from a typical meta-
analysis as I 2 = 100%×(Q − df)/Q, where Q is Cochran’s
heterogeneity statistic and df the degrees of freedom.
Negative values of I 2 are put equal to zero so that I 2 lies
between 0% and 100%. A value of 0% indicates no
observed heterogeneity, and larger values show
increasing heterogeneity.
Examples of values of I 2
The principal advantage of I 2 is that it can be calculated
and compared across meta-analyses of different sizes,
of different types of study, and using different types of
outcome data. Table 1 gives I 2 values for six published
meta-analyses along with 95% uncertainty intervals.
The upper limits of these intervals show that
conclusions of homogeneity in meta-analyses of small
numbers of studies are often unjustified.11 13 15–19
The tamoxifen and streptokinase meta-analyses, in
which all the included studies found similar effects,16 17
have I 2 values of 3% and 19% respectively. These indi-
cate little variability between studies that cannot be
explained by chance. For the review comparing
drop-outs on selective serotonin reuptake inhibitors
with tricyclic antidepressants, I 2 is 26%, indicating that
although the heterogeneity is highly significant, it is a
small effect.
The reviews of trials of magnesium after myocar-
dial infarction (I 2 = 63%) and case-control studies
investigating the effects of electromagnetic radiation
on leukaemia (69%) both included studies with diverse
results. The high I 2 values show that most of the
variability across studies is due to heterogeneity rather
than chance. Although no significant heterogeneity
was detected in the review of amantadine,11 the incon-
sistency was moderately large (I 2 = 44%).
Figure 2 shows the observed values of I 2 from 509
meta-analyses in the Cochrane Database of Systematic
Reviews. Almost half of these meta-analyses (250) had no
inconsistency (I 2 = 0%). Among meta-analyses with
some heterogeneity, the distribution of I 2 is roughly flat.
Further applications of I 2
I 2 can also be helpful in investigating the causes and
type of heterogeneity, as in the three examples below.
Methodological subgroups
Figure 3 shows the six case-control studies of magnetic
fields and leukaemia broken down into two subgroups
based on assessment of their quality.19 If heterogeneity
is identified in a meta-analysis a common option is to
subgroup the studies. Because of loss of power,
non-significant heterogeneity within a subgroup may
be due not to homogeneity but to the smaller number
of studies. Here, the P values for the heterogeneity test
are higher for the two subgroups (P = 0.3 and
P = 0.009) than for the complete data (P = 0.007),
which suggests greater consistency within the sub-
groups. However, the values of I 2 show that the three
low quality studies are more inconsistent (I 2 = 79%)
than all six (I 2 = 69%) (table 2). Substantially less incon-
sistency exists among the high quality studies (I 2
= 15%), although uncertainty intervals for all of the I2
values are wide.
Table 1 Heterogeneity statistics for examples of meta-analyses from the literature. Meta-analyses were conducted using either meta
or metan in STATA15
Topic Outcome/analysis Effect measure
No of
studies
Heterogeneity test I 2 (95% uncertainty
interval)*Q df P
Tamoxifen for breast
cancer16
Mortality Peto odds ratio 55 55.9 54 0.40 3 (0 to 28)
Streptokinase after
myocardial infarction17
Mortality Odds ratio 33 39.5 32 0.17 19 (0 to 48)
Selective serotonin
reuptake inhibitors for
depression13
Drop-out Odds ratio 135 179.9 134 0.005 26 (7 to 40)
Magnesium for acute
myocardial infarction18
Death Odds ratio 16 40.2 15 0.0004 63 (30 to 78)
Magnetic fields and
leukaemia19
All studies Odds ratio 6 15.9 5 0.007 69 (26 to 87)
Amantadine11 Prevention of influenza Odds ratio 8 12.44 7 0.09 44 (0 to 75)
df=degrees of freedom.
*Values of I 2 are percentages. 95% uncertainty intervals are calculated as proposed by Higgins and Thompson.14
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Fig 2 Distribution of observed values of I 2 based on odds ratios
from 509 meta-analyses of dichotomous outcomes in the Cochrane
Database of Systematic Reviews. Data are from the first subgroup (if
any) in the first meta-analysis (if any) in each review, if it involved a
dichotomous outcome and at least two trials with events.
Meta-analyses conducted with metan in STATA15
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Heterogeneity related to choice of effect measure
A systematic review of clinical trials of human albumin
administration in critically ill patients concluded that
albumin may increase mortality.20 These studies had no
inconsistency in risk ratio estimates (I 2 = 0%) and a
narrow uncertainty interval. Table 2 shows the hetero-
geneity statistics for risk differences as well as for risk
ratios. Six trials with no deaths in either treatment
group do not contribute information on risk ratios, but
they all provide estimates of risk differences. Using P
values to decide which scale is more consistent with the
data21 is inappropriate because of the differing
numbers of studies. I 2 values may validly be compared
and show that the risk differences are less homogene-
ous, as is often the case.22
Clinically important subgroups
I 2 can also be used to describe heterogeneity among
subgroups. Table 2 includes results for the outcome of
recurrence in the meta-analysis of trials of tamoxifen
for women with early breast cancer. There was highly
significant (P = 0.00002) and important heterogeneity
(I 2 = 50%) among the trials.16 However, a potentially
important source of heterogeneity is the duration of
treatment. The authors divided the trials into three
duration categories and presented an overall hetero-
geneity test, a test comparing the three subgroups, and
a test for heterogeneity within the subgroups. I 2 values
corresponding to each test show that 96% of the
variability observed among the three subgroups
cannot be explained by chance. This is not clear from
the P values alone. The extreme inconsistency among
all 55 trials in the odds ratios for recurrence (I 2 = 50%)
is substantially reduced (I 2 = 13%) once differences in
treatment duration are accounted for.
How much is too much heterogeneity?
A naive categorisation of values for I 2 would not be
appropriate for all circumstances, although we would
tentatively assign adjectives of low, moderate, and high
to I 2 values of 25%, 50%, and 75%. Figure 2 shows that
about a quarter of meta-analyses have I 2 values over
50%. Quantification of heterogeneity is only one com-
ponent of a wider investigation of variability across
studies, the most important being diversity in clinical
and methodological aspects. Meta-analysts must also
consider the clinical implications of the observed
degree of inconsistency across studies. For example,
interpretation of a given degree of heterogeneity
across several studies will differ according to whether
the estimates show the same direction of effect.
Advantages of I 2
• Focuses attention on the effect of any heterogeneity
on the meta-analysis
• Interpretation is intuitive—the percentage of total
variation across studies due to heterogeneity
• Can be accompanied by an uncertainty interval
• Simple to calculate and can usually be derived from
published meta-analyses
• Does not inherently depend on the number of
studies in the meta-analysis
• May be interpreted similarly irrespective of the type
of outcome data (eg dichotomous, quantitative, or time
to event) and choice of effect measure (eg odds ratio
or hazard ratio)
• Wide range of applications
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Fig 3 Meta-analyses of six case-control studies relating residential
exposure to electromagnetic fields to childhood leukaemia.19
Summary odds ratio calculated by random effects method
Table 2 More advanced applications of I 2 for assessing heterogeneity in three published meta-analyses. Meta-analyses were
conducted with either meta or metan in STATA15
Topic Outcome/analysis Effect measure No of studies
Heterogeneity test I 2 (95% uncertainty
intervals)*Q df P
Magnetic fields and
leukaemia19
All studies Odds ratio 6 15.9 5 0.007 69 (26 to 87)
High quality Odds ratio 3 2.4 2 0.31 17 (0 to 91)
Low quality Odds ratio 3 9.4 2 0.009 79 (32 to 94)
Human albumin for
critically ill20
Death Risk ratio 24† 15.3 23 0.88 0 (0 to 17)
Death Risk difference 30 36.7 29 0.15 21 (0 to 50)
Tamoxifen to prevent
recurrence of breast
cancer17
All studies Peto odds ratio 55 108.2 54 0.00002 50 (32 to 63)
Total within groups‡ Peto odds ratio — 59.9 52 0.21 13 (0 to 39)
Between groups‡ Peto odds ratio 3 groups 48.3 2 <0.00001 96 (91 to 98)
df=degrees of freedom,
*Values of I 2 are percentages. 95% uncertainty intervals are calculated as proposed by Higgins and Thompson.14
†Studies with no events in either treatment group do not contribute to this analysis.
‡Subgroup defined by duration of tamoxifen treatment.
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An alternative quantification of heterogeneity in a
meta-analysis is the among-study variance (often called
2), calculated as part of a random effects meta-analysis.
This is more useful for comparisons of heterogeneity
among subgroups, but values depend on the treatment
effect scale. We believe, I 2 offers advantages over exist-
ing approaches to the assessment of heterogeneity
(box). Focusing on the effect of heterogeneity also
avoids the temptation to perform so called two stage
analyses, in which the meta-analysis strategy (fixed or
random effects method) is determined by the result of
a statistical test. Such strategies have been found to be
problematic.23 24 We therefore believe that I 2 is
preferable to the test of heterogeneity when assessing
inconsistency across studies.
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Summary points
Inconsistency of studies’ results in a meta-analysis
reduces the confidence of recommendations
about treatment
Inconsistency is usually assessed with a test for
heterogeneity, but problems of power can give
misleading results
A new quantity I 2, ranging from 0-100%, is
described that measures the degree of
inconsistency across studies in a meta-analysis
I 2 can be directly compared between
meta-analyses with different numbers of studies
and different types of outcome data
I 2 is preferable to a test for heterogeneity in
judging consistency of evidence
One hundred years ago
The open-air treatment of surgical tuberculosis
The profound and far-reaching effects of what is popularly
known as the open-air treatment of consumption are only just
beginning to be appreciated. Having originated merely with an
attempt to cure or alleviate a disease which afflicts every race of
mankind, it has directed attention to the physical and social
conditions which lead to it, and clearly indicates the direction in
which reform is urgently needed if deterioration of the physique
of modern urban communities is to be arrested.
What, then, is this great discovery embodied in the open-air
treatment of consumption? Absurd as it may sound, it is nothing
but the rediscovery of the vis medicatrix Naturae and of the value
of unpolluted air. That the body possesses a certain power of
recovering from illness and repairing wounds, and that pure air is
beneficial to health, have always been familiar facts; but familiar
facts are just those which are most constantly disregarded in
practice. It is one of the great merits of the open-air treatment of
consumption that it is rapidly popularizing the conception that
polluted air is as much to be avoided as polluted water. More
important still, has been the effect of the open-air treatment in
refuting deeply-rooted superstitions as to the evil effects of
exposure to atmospheric changes, and in directing attention to
the real enemy—namely, dust and dirt, especially the organic dirt
which emanates from the animal body.
There can be no great progress in public health until all classes
recognize that the first essential of health is minute cleanliness of
body, raiment, food, and dwelling-house. How far we are from this
ideal, even among the well-to-do classes, every doctor knows.
(BMJ 1903;ii:986)
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